Department of Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
J Gastrointest Surg. 2010 Oct;14(10):1483-91. doi: 10.1007/s11605-010-1322-8. Epub 2010 Sep 8.
Factors associated with the risk of progression of Barrett's esophagus remain unclear, and the impact of therapy on this risk remains uncertain. The aim of this study was to assess patients followed long-term after anti-reflux surgery for Barrett's esophagus.
A retrospective review was performed of all patients with Barrett's who underwent anti-reflux surgery from 1989 to 2009 and had ≥5 years of follow-up.
There were 303 patients and 75 had follow-up ≥5 years. Median follow-up time for the 75 patients was 8.9 years (range 5-18). Regression was seen in 31%. Progression occurred in 8%, and these patients were significantly more likely to have a failed fundoplication (67% vs. 16%, p = 0.0129). The rate of progression from non-dysplastic Barrett's to high-grade dysplasia or cancer was 0.8% per patient year, and was seven times higher in patients with a failed fundoplication.
Compared to the accepted rate of progression of non-dysplastic Barrett's to high-grade dysplasia or cancer of 1.0% per patient year, anti-reflux surgery reduces this rate during long-term follow-up. The rate of progression was significantly lower in patients with an intact compared to a disrupted fundoplication, further suggesting that anti-reflux surgery can alter the natural history of Barrett's esophagus.
与 Barrett 食管进展风险相关的因素仍不清楚,治疗对这种风险的影响也不确定。本研究旨在评估长期接受 Barrett 食管抗反流手术后的患者。
对 1989 年至 2009 年期间接受抗反流手术且随访时间≥5 年的所有 Barrett 食管患者进行回顾性分析。
共有 303 例患者,其中 75 例随访时间≥5 年。75 例患者的中位随访时间为 8.9 年(范围 5-18 年)。31%的患者出现了缓解。8%的患者发生了进展,这些患者的胃底折叠术失败的可能性明显更高(67%比 16%,p=0.0129)。非异型增生性 Barrett 食管进展为高级别异型增生或癌症的年发生率为 0.8%,胃底折叠术失败患者的发生率则高出 7 倍。
与非异型增生性 Barrett 食管进展为高级别异型增生或癌症的 1.0%的公认年发生率相比,抗反流手术可在长期随访中降低这一发生率。与胃底折叠术未受损的患者相比,胃底折叠术失败的患者的进展率明显更低,这进一步表明抗反流手术可以改变 Barrett 食管的自然病程。